Atezolizumab in the treatment of metastatic triple-negative breast cancer

References

• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–923.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108–2121. .
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523–533.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753–763.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741–751.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. Harnessing immune checkpoints for cancer therapy. Immunotherapy. 2018;10(14):1265–1284.
   PubMed Web of Science ®Google Scholar
• Webb ES, Liu P, Baleeiro R, et al. Immune checkpoint inhibitors in cancer therapy. J Biomed Res. 2018;32(5):317–326.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. .
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069–1086. .
   PubMed Web of Science ®Google Scholar
• Weintraub K. Drug development: releasing the brakes. Nature. 2013;504(7480):S6–8.
   PubMed Web of Science ®Google Scholar
• Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019;17(1):90.
   PubMed Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016;2(10):1354–1360.
   PubMed Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–241. .
   PubMed Web of Science ®Google Scholar
• Garcia-Teijido P, Cabal ML, Fernandez IP, et al. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: the Future of Immune Targeting. Clin Med Insights Oncol. 2016;10(Suppl 1):31–39.
   PubMedGoogle Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50.
   PubMed Web of Science ®Google Scholar
• Narang P, Chen M, Sharma AA, et al. The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019;19(1):200.
   PubMed Web of Science ®Google Scholar
• Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17–37.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. .
   PubMed Web of Science ®Google Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307–314.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Yu J, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel). 2020;12:3.
   Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–370.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671–686.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34(21):2460–2467.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405–411.
   PubMed Web of Science ®Google Scholar
• Cortés J, Lipatov O, Im S, et al. KEYNOTE-119: phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2019;30(suppl_5):v851–v934.
   Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928.
   PubMed Web of Science ®Google Scholar
• Dalenc F, Garberis I, Filleron T, et al. Abstract GS3-02: durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. Cancer Res. 2020;80(4 Supplement):GS3-02-GS3-02.
   Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. .
   PubMed Web of Science ®Google Scholar
• Shah NJ, Kelly WJ, Liu SV, et al. Product review on the Anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother. 2018;14(2):269–276.
   PubMed Web of Science ®Google Scholar
• Tecentriq summary of product characteristics. 2017. [Cited 2019 Oct 19]. Available from: www.ema.europa.eu/documents/product-information/tecentriq-epar-product-information_en.pdf
   Google Scholar
• Tecentriq prescribing information. 2019. [Cited 2019 Oct 19]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf
   Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019;5(1):74–82. .
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74–88.
   PubMed Web of Science ®Google Scholar
• Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25.
   PubMed Web of Science ®Google Scholar
• Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther. 2017;10:101–112.
   PubMed Web of Science ®Google Scholar
• Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219–235.
   PubMed Web of Science ®Google Scholar
• Pol J, Vacchelli E, Aranda F, et al. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4(4):e1008866.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.
   PubMed Web of Science ®Google Scholar
• Mackenzie KJ, Carroll P, Martin CA, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548(7668):461–465.
   PubMed Web of Science ®Google Scholar
• Harding SM, Benci JL, Irianto J, et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466–470.
   PubMed Web of Science ®Google Scholar
• Adams S, Diamond JR, Hamilton E, et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2019;5(3):334–342. .
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Lawson NL, Dix CI, Scorer PW, et al. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathol. 2019. DOI:10.1038/s41379-019-0372-z.
   PubMed Web of Science ®Google Scholar
• Torlakovic E, Lim HJ, Adam J, et al. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2020;33(1):4–17.
   PubMed Web of Science ®Google Scholar
• Emens L, Loi S, Rugo H, et al. Abstract GS1-04: iMpassion130: efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Cancer Res. 2019;79(4 Supplement):GS1-04-GS1-04.
   Web of Science ®Google Scholar
• Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130 [Abstract LBA20]. in ESMO Congress 2019; September 27-October 1, 2019. 2019. Barcelona, Spain: Annals of Oncology.
   Google Scholar
• Cortes J, Andre F, Goncalves A, et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 2019;15(17):1951–1961.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–e186. .
   PubMed Web of Science ®Google Scholar
• Yan Y, Kumar AB, Finnes H, et al. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol. 2018;9:1739.
   PubMed Web of Science ®Google Scholar